 | |
- close
- close
Affymax to Highlight Hematide™ Data at the American Society of Nephrology Renal Week 2009
Business Wire
Oct 22, 2009
Affymax, Inc. (Nasdaq:AFFY) today announced multiple presentations at the American Society of Nephrology (ASN) Renal Week 2009 taking place October 27 through November 1 in San Diego.
Affymax’s drug, Hematide™, is currently in development with Takeda Pharmaceutical Company Limited for the treatment of anemia associated with chronic renal failure. Affymax and investigators will make multiple presentations highlighting Hematide preclinical and clinical data in various treatment settings. These include preliminary results of a Phase 2 trial in hemodialysis (HD) patients who are not on an erythropoiesis stimulating agent (ESA), and interim results from an ongoing Phase 2 study in patients with antibody-mediated pure red cell aplasia (Ab+PRCA).
Details of Hematide presentations at ASN are as follows:
*Note: All times are listed in Pacific Time
|
Friday, October 30: |
||||||||||
| -- | Poster session: Preliminary Analysis of Once-Monthly Hematide Efficacy and Safety in HD Patients Not on ESA Treatment | |||||||||
| Abstract F-PO1094: 10:00 AM - 12:00 PM | ||||||||||
| -- | Poster session: Efficacy and Safety of Hematide in Patients with Anti-Erythropoietin (EPO) Antibody-Mediated Pure Red Cell Aplasia (Ab+PRCA) | |||||||||
| Abstract F-PO1099: 10:00 AM - 12:00 PM | ||||||||||
|
Saturday, October 31: |
||||||||||
| -- | Poster session: Hematide Demonstrates Prolonged In Vitro Binding to the Human Erythropoietin Receptor | |||||||||
| Abstract SA-PO2430: 10:00 AM - 12:00 PM | ||||||||||
| -- | Poster session: Hematide Stimulates Similar Signaling Pathways to EPO in UT-7/EPO Cells, but with Different Kinetics and Relative Potency | |||||||||
| Abstract SA-PO2431: 10:00 AM - 12:00 PM | ||||||||||
| -- | Poster session: Hematide Is Minimally Immunogenic in Nonclinical Studies | |||||||||
| Abstract SA-PO2432: 10:00 AM - 12:00 PM | ||||||||||
Company Webcast
Affymax will host an investor webcast with Dr. Richard Lafayette, clinical chief of nephrology and associate professor of medicine at Stanford University Medical Center, and Dr. Iain MacDougall, nephrology consultant at the Department of Renal Medicine, King’s College Hospital. Dr. Lafayette will provide background on managing anemia in patients with chronic kidney disease. Dr. MacDougall will discuss pure red cell aplasia (PRCA) a rare, serious and debilitating autoimmune disorder, which can occur when the body produces neutralizing antibodies to the currently marketed recombinant human erythropoietins.
The webcast will take place on Friday, October 30th from 7:00-8:00 a.m. PT, and may be accessed from the investors section of the company's website at www.affymax.com. A replay will also be available for 30 days following the presentation.
About Hematide
Hematide is a novel synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an erythropoiesis stimulating agent (ESA).
Affymax and Takeda are collaborating on the development of Hematide and plan to co-commercialize the product once approved in the United States. The product, upon approval, will be commercialized in the European Union by Takeda. Phase 3 clinical trials are being conduced to investigate the potential for Hematide to treat anemia associated with chronic renal disease.
About Anemia in Chronic Renal Failure (CRF)
Anemia in CRF affects many individuals with Chronic Kidney Disease (CKD). According to the National Kidney Foundation, 26 million Americans - 1 in 9 U.S. adults - have CKD. Anemia develops in the early stages of CKD and worsens as patients progress towards total kidney failure and need a dialysis machine to eliminate waste and water from their blood. In severe or prolonged cases of anemia, the lack of oxygen in the blood can cause serious and sometimes fatal damage to the heart and other organs. Benefits of anemia correction in patients with CKD include decreased morbidity, hospitalization, and mortality.1
About Affymax, Inc.
Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. For additional information, please visit www.affymax.com.
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
| ||||||
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
|
|
